Reading Time: 2 minutes

Greenyn Biotechnology received USFDA NDI acknowledgement without objection for Antrodia cinnamomea mycelia “Antromax”

Taipei, Taiwan–(Newsfile Corp. – May 12, 2021) – On April 12th, Greenyn Biotechnology Corporation hosted a seminar – “The international development of Taiwan’s Antrodia cinnamomea and its clinical application,” and announced Antromax’s acknowledgement without objection by USFDA NDI. It was a great feat for Greenyn, and will certainly boost the morale of the Antrodia industry to devote more resources in the US market.

A. cinnamomea is an edible fungus that grows on the endangered Cinnamomum kanehirae tree, which is found only in Taiwan. This indigenous fungus is traditionally used to ameliorate liver disorders, hangovers, fatigue, and enhance immunity. “Ruby of Taiwan” was given to this miracle fungus.

®– dripping pills, mycelia powder, emulsion powder (left to right).

If you cannot view this graphic, please visit:

Health food of Antromax
® in livercare in Taiwan (left) and Antromax® complex beverage (right).

If you cannot view this graphic, please visit:

Health benefits of Antromax

During the seminar, Dr. Kao Shung-te, Attending Physician of China Medical University Hospital, shared the findings of Antromax in the clinical adjuvant treatment for hepatitis B. “Through medical trials, it is discovered that Antromax have an adjuvant treatment effect combined with the hepatitis B medicine. The liver function indexes are improved, and there are no adverse effect on the biochemical values of the blood and urine.”

In Addition, Dr. Houng Jer-yiing, Associate Dean of the I-Shou University Medical School, shared that the bioavailability of Antromax in different dosage forms have similar adjuvant effects -lowering liver function indexes, liver fat accumulation and alcohol-related liver injuries, as well as enhancing activities of antioxidant enzymes.

Greenyn’s facility is built to the international standards in the Central Taiwan Science Park with capacity of up-to 12 metric tons annually which is sufficient for the global markets. Dr. Hsu says, “At present, we will focus on the US and Europe markets, and next we might start to promote in Asia such as Korea, Southeast Asian countries and Australia.” In view of the US herbal supplements market worth USD 9.6 billion, Greenyn is honored to lead Taiwan’s biotech industry to promote A. cinnamomea in the US markets. It is foreseeable that the health benefit of A. cinnamomea to the world during COVID-19 will create another pride for Taiwan.

Cannot view this video? Visit:

Media Contact

Greenyn Biotechnology Co. Ltd.
Phone: +886-968- 191-636
Contact: Wayne Wei
Email: [email protected]

To view the source version of this press release, please visit

Powered by WPeMatico